194 related articles for article (PubMed ID: 26679376)
21. [Expression of CK5/6 and CK17 and its correlation with prognosis of triple-negative breast cancer patients].
Liu ZB; Wu J; Ping B; Feng LQ; Shen ZZ; Shao ZM
Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):610-4. PubMed ID: 19102940
[TBL] [Abstract][Full Text] [Related]
22. Association between common risk factors and molecular subtypes in breast cancer patients.
Turkoz FP; Solak M; Petekkaya I; Keskin O; Kertmen N; Sarici F; Arik Z; Babacan T; Ozisik Y; Altundag K
Breast; 2013 Jun; 22(3):344-50. PubMed ID: 22981738
[TBL] [Abstract][Full Text] [Related]
23. Pure or mixed-type invasive lobular carcinoma?
Bulut N; Dede DS; Sari E; Altundag K
Hum Pathol; 2008 Jul; 39(7):1121; author reply 1121. PubMed ID: 18570979
[No Abstract] [Full Text] [Related]
24. Male breast cancer: immunohistochemical subtypes and clinical outcome characterization.
Sánchez-Muñoz A; Román-Jobacho A; Pérez-Villa L; Sánchez-Rovira P; Miramón J; Pérez D; Sáez MI; de Luque V; Medina L; Ramírez-Tortosa CL; Vicioso L; Medina JA; Ribelles N; Alba E
Oncology; 2012; 83(4):228-33. PubMed ID: 22907070
[TBL] [Abstract][Full Text] [Related]
25. Coordinated expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas.
Fernandes RC; Bevilacqua JL; Soares IC; Siqueira SA; Pires L; Hegg R; Carvalho FM
Histopathology; 2009 Sep; 55(3):346-52. PubMed ID: 19723150
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathologic features of breast carcinomas classified by biomarkers and correlation with microvessel density and VEGF expression: a study from Thailand.
Chuangsuwanich T; Pongpruttipan T; O-Charoenrat P; Komoltri C; Watcharahirun S; Sa-Nguanraksa D
Asian Pac J Cancer Prev; 2014; 15(3):1187-92. PubMed ID: 24606439
[TBL] [Abstract][Full Text] [Related]
27. Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index.
Ono M; Tsuda H; Yoshida M; Shimizu C; Kinoshita T; Tamura K
Clin Breast Cancer; 2017 Feb; 17(1):41-47. PubMed ID: 27477822
[TBL] [Abstract][Full Text] [Related]
28. Pregnancy-associated plasma protein-A expression in human breast cancer.
Mansfield AS; Visscher DW; Hart SN; Wang C; Goetz MP; Oxvig C; Conover CA
Growth Horm IGF Res; 2014 Dec; 24(6):264-7. PubMed ID: 25468445
[TBL] [Abstract][Full Text] [Related]
29. Protein expression profile and prevalence pattern of the molecular classes of breast cancer--a Saudi population based study.
Al Tamimi DM; Shawarby MA; Ahmed A; Hassan AK; AlOdaini AA
BMC Cancer; 2010 May; 10():223. PubMed ID: 20492711
[TBL] [Abstract][Full Text] [Related]
30. Inference of the Basal epithelial phenotype in breast carcinoma from differential marker expression, using tissue microarrays in triple negative breast cancer and women younger than 35.
Nassar A; Sussman ZM; Lawson D; Cohen C
Breast J; 2012 Sep; 18(5):399-405. PubMed ID: 22882580
[TBL] [Abstract][Full Text] [Related]
31. Subtypes of Breast Cancer in Lao P.D.R.: A Study in a Limited-Resource Setting.
Luangxay T; Virachith S; Hando K; Vilayvong S; Xaysomphet P; Arounlangsy P; Phongsavan K; Mieno MN; Honma N; Kitagawa M; Sawabe M
Asian Pac J Cancer Prev; 2019 Feb; 20(2):589-594. PubMed ID: 30806064
[TBL] [Abstract][Full Text] [Related]
32. Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort study.
Dawood S; Hu R; Homes MD; Collins LC; Schnitt SJ; Connolly J; Colditz GA; Tamimi RM
Breast Cancer Res Treat; 2011 Feb; 126(1):185-92. PubMed ID: 20711652
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathlogic and immunohistochemical characteristics of triple negative invasive lobular carcinoma.
Koo JS; Jung W
Yonsei Med J; 2011 Jan; 52(1):89-97. PubMed ID: 21155040
[TBL] [Abstract][Full Text] [Related]
34. Immunohistochemical profile of high-grade ductal carcinoma in situ of the breast.
Perez AA; Rocha RM; Balabram D; Souza Áda S; Gobbi H
Clinics (Sao Paulo); 2013 May; 68(5):674-8. PubMed ID: 23778408
[TBL] [Abstract][Full Text] [Related]
35. Hormone receptors and HER2 expression in primary breast carcinoma and corresponding lymph node metastasis: do we need both?
Raica M; Cîmpean AM; Ceausu RA; Fulga V; Nica C; Rudico L; Saptefrati L
Anticancer Res; 2014 Mar; 34(3):1435-40. PubMed ID: 24596391
[TBL] [Abstract][Full Text] [Related]
36. Active smoking and risk of Luminal and Basal-like breast cancer subtypes in the Carolina Breast Cancer Study.
Butler EN; Tse CK; Bell ME; Conway K; Olshan AF; Troester MA
Cancer Causes Control; 2016 Jun; 27(6):775-86. PubMed ID: 27153846
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
38. Association of immunohistochemically defined molecular subtypes with clinical response to presurgical chemotherapy in patients with advanced breast cancer.
Khokher S; Qureshi MU; Mahmood S; Nagi AH
Asian Pac J Cancer Prev; 2013; 14(5):3223-8. PubMed ID: 23803108
[TBL] [Abstract][Full Text] [Related]
39. Expression of DDR1 and DVL1 in invasive ductal and lobular breast carcinoma does not correlate with histological type, grade and hormone receptor status.
Ameli F; Rose IM; Masir N
Asian Pac J Cancer Prev; 2015; 16(6):2385-90. PubMed ID: 25824769
[TBL] [Abstract][Full Text] [Related]
40. Basal markers and prognosis in luminal breast cancer.
Engstrøm MJ; Valla M; Bofin AM
Breast Cancer Res Treat; 2017 Jun; 163(2):207-217. PubMed ID: 28258354
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
